A protein on the surface of cells that acts like a receptor for a signalling molecule called lysophosphatidic acid, triggering changes in cell growth, movement and inflammation. It matters to investors because blocking or activating this receptor is a potential way to treat diseases—so companies developing drugs or diagnostics aimed at it face clinical, regulatory and commercial risks and rewards; think of the receptor as a light switch that drugmakers try to turn on or off to change a disease’s course.
lpa1 antagonistsmedical
LPA1 antagonists are drugs that block a specific cell surface receptor called LPA1, which responds to a signaling molecule involved in inflammation, tissue scarring and some cancer behaviors. By preventing that receptor from receiving harmful signals—like putting a cap on a keyhole—they can slow or stop processes that damage organs or help tumors spread, so investors watch them as potential treatments that could address chronic diseases with large markets.
alveolar epithelial cell apoptosismedical
Alveolar epithelial cell apoptosis is the programmed death of the thin cells that line the air sacs in the lungs. Like a controlled demolition of damaged rooms in a building, this process can signal lung injury or disease progression and is important to investors because it affects the safety and effectiveness of respiratory drugs, the potential market for therapies, and regulatory or clinical trial outcomes for companies developing lung treatments.
in vitromedical
In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.
pulmonary fibrosismedical
Pulmonary fibrosis is a condition where lung tissue becomes progressively scarred and stiff, reducing the lungs’ ability to move oxygen into the blood—think of a sponge that gradually turns rigid and less absorbent. For investors it matters because the disease drives demand for treatments, fuels clinical trials and regulatory reviews, and affects healthcare costs, insurance liabilities, workforce productivity and the commercial prospects of drugs or medical devices aimed at respiratory conditions.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SAN DIEGO--(BUSINESS WIRE)--
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 2026.
The following abstracts are posted on ATS 2026’s online itinerary planner for registered users.
Title: PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists With Distinct Lung Occupancy Profiles and Vascular Effects
Presenter: Daniel S. Lorrain, Ph.D., Chief Scientific Officer at Contineum Therapeutics
Poster: P155
Date and Time: Monday, May 18, 2026 from 11:30 a.m. ET-1:15 p.m. ET
Session: From Target Discovery to Clinical Translation in Pulmonary Fibrosis
Title: LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro
Presenter: Michael Poon, Ph.D., VP, Biology at Contineum Therapeutics
Poster: P156
Date and Time: Monday, May 18, 2026 from 11:30 a.m. ET-1:15 p.m. ET
Session: From Target Discovery to Clinical Translation in Pulmonary Fibrosis
Posters will be available to view during ATS 2026 at the stated times for registered users and on the Publications page of Contineum’s website.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com.
